Pliant Therapeutics, INC Schedule 13G passive stakes

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.9% of Pliant Therapeutics, Inc. common stock as of June 30, 2026.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a 5.0% beneficial ownership stake in Pliant Therapeutics, Inc. through a Schedule 13G filing.

Citadel entities and Kenneth Griffin have jointly disclosed a 4.9% beneficial ownership stake in Pliant Therapeutics, Inc. common stock.

Citadel Advisors and affiliated entities, including Kenneth Griffin, have disclosed a collective 4.9% passive beneficial ownership in Pliant Therapeutics, Inc. common stock.

Morgan Stanley has reported a reduction in its beneficial ownership of Pliant Therapeutics, Inc. common stock to below 5%.

Woodline Partners LP has reported a 7.3% beneficial ownership stake in Pliant Therapeutics, Inc., holding over 4.5 million shares.

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in Pliant Therapeutics, Inc., holding 0% of the common stock.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has reported a 6.7% beneficial ownership stake in Pliant Therapeutics, Inc.

Deep Track Capital and its affiliates have disclosed a 6.43% beneficial ownership stake in Pliant Therapeutics, Inc., holding 3,947,807 shares of common stock.

Morgan Stanley has reported a 6.1% passive beneficial ownership stake in Pliant Therapeutics, Inc., holding 3,737,335 shares of common stock.

The Vanguard Group has reported a 4.89% beneficial ownership stake in Pliant Therapeutics Inc., primarily holding sole dispositive power over its common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 3.4% beneficial ownership stake in Pliant Therapeutics Inc. common stock.

Paradigm BioCapital Advisors LP and its affiliated entities have filed an amendment to their Schedule 13G, indicating they no longer hold a reportable beneficial ownership stake in Pliant Therapeutics, Inc. as of March 31, 2025.

T. Rowe Price Associates, Inc. has filed an Amendment No. 2 to Schedule 13G, disclosing its beneficial ownership of 0.1% of Pliant Therapeutics Inc.'s common stock as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, indicating a reduction in their beneficial ownership of Pliant Therapeutics Inc. common stock to 0.2% of the outstanding class.

Redmile Group, LLC and its principal Jeremy C. Green have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.8% in Pliant Therapeutics, Inc. as of December 31, 2024.